肥胖：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 受高效療法和治療手段日益普及的推動，肥胖症市場正在迅速擴張。
• 法國肥胖症治療市場預計將從 2025 年的 4.1 億美元成長到 2035 年的 15.7 億美元，複合年成長率高達 14-15%。
• 德國肥胖症患者人數預計將以約 7% 的複合年成長率成長，這將顯著擴大目標市場。

肥胖症概述

肥胖是一種複雜的慢性疾病，其特徵是體內脂肪過度堆積，這會損害健康並增加多種併發症的風險，包括第2型糖尿病、心血管疾病、某些癌症和肌肉骨骼疾病。肥胖是由遺傳、環境、行為和代謝因素相互作用引起的，但其核心因素是能量失衡，即熱量攝取超過熱量消耗。

診斷通常基於體重指數（BMI≥30 kg/m²），但腰圍和身體組成等其他指標可以更詳細地了解心血管代謝風險。除了影響身體健康外，肥胖還會導致生活品質下降、心理困擾和社會歧視。

人們越來越認知到，這種疾病是一種受生物因素控制的慢性疾病，需要長期管理。治療方法是多方面的，包括：

• 生活方式改善和營養指導
• 身體活動和行為療法
• 藥物治療
• 嚴重病例的減重手術

近年來，治療手段的進步，特別是GLP-1和雙重腸促胰島素製劑的出現，顯著改善了臨床療效，實現了持續減重，並改變了治療模式。儘管取得了這些進展，肥胖仍然是全球面臨的重大公共衛生挑戰，需要製定可擴展的預防策略和個人化的長期照護模式。

主要亮點

• 德國肥胖症患者人數預計將從 2025 年的 720 萬大幅增加到 2035 年的 1,420 萬，呈現高速成長態勢（年複合成長率為 7%）。
• 肥胖是一種患病率高、醫療負擔重的疾病，相關的併發症會導致大量的長期醫療費用。
• 雖然患者人數眾多，但治療率仍然很低，許多患者主要透過改變生活方式進行治療。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興療法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Hanmi Pharmaceutical Company Limited
• Tonghua Dongbao Pharmaceutical Co.,Ltd
• Aphaia Pharma US LLC
• NeuroBiogen Co., Ltd
• Eli Lilly and Company
• MindRank AI Ltd
• Pfizer
• Kailera
• Glyscend, Inc.
• NodThera Limited
• Palatin Technologies, Inc
• BrightGene Bio-Medical Technology Co., Ltd.
• Aardvark Therapeutics, Inc.
• Alnylam Pharmaceuticals
• Guangdong Raynovent Biotech Co., Ltd
• Innovent Biologics（Suzhou）Co. Ltd.
• Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
• Fujian Shengdi Pharmaceutical Co., Ltd.
• Arrowhead Pharmaceuticals
• Hudson Biotech
• Zomagen Biosciences Ltd.
• Corxel Pharmaceuticals
• Regeneron Pharmaceuticals
• Regor Pharmaceuticals Inc.
• Boehringer Ingelheim
• Novo Nordisk A/S
• Skye Bioscience, Inc.
• Shionogi
• Amgen
• Rhythm Pharmaceuticals, Inc.
• Vanda Pharmaceuticals
• Kallyope Inc.
• Metsera, a wholly owned subsidiary of Pfizer
• S1 Biopharma, Inc.
• Biophytis
• AstraZeneca
• Shandong Suncadia Medicine Co., Ltd.
• Biohaven Therapeutics Ltd.
• Beijing QL Biopharmaceutical Co.,Ltd
• Rose Pharma Inc
• Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Vincentage Pharma Co., Ltd
• CSPC Baike（Shandong）Biopharmaceutical Co., Ltd.
• Gan and Lee Pharmaceuticals, USA
• Verdiva Bio Dev Limited
• Gan &Lee Pharmaceuticals.
• Carmot Therapeutics, Inc.
• Exerkine Corporation
• Terns, Inc.
• Chendu DIAO Pharmaceutical Group CO., LTD.
• Hangzhou Sciwind Biosciences Co., Ltd.
• The United Bio-Technology（Hengqin）Co., Ltd.
• Scholar Rock, Inc.
• Biomed Industries, Inc.
• Ikaria Bioscience Pty Ltd
• Hoffmann-La Roche
• HK inno.N Corporation
• Actimed Therapeutics Ltd
• Inversago Pharma Inc.
• Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.
• Immunwork, Inc.
• Veru Inc.
• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
• Neuraly, Inc.
• ARKAY Therapeutics

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前療法
  • 重點
  • 診斷和治療過程/演算法
  • 主要療法概述及KOL洞察
• 新興療法
  • 重點
  • 值得關注的後期新療法—概述、市場上市預期和KOL洞察
  • 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

• 主要未滿足的需求以及透過新興療法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Obesity Market Outlook

Thelansis's "Obesity Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Obesity treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Obesity Overview

Obesity is a complex, chronic disease characterized by excessive accumulation of body fat that impairs health and increases the risk of multiple comorbidities, including type 2 diabetes, cardiovascular disease, certain cancers, and musculoskeletal disorders. It arises from an interplay of genetic, environmental, behavioral, and metabolic factors, with energy imbalance-calories consumed exceeding calories expended-being the central driver.

Diagnosis is typically based on body mass index (BMI ≥30 kg/m2), though additional measures such as waist circumference and body composition provide better insight into cardiometabolic risk. Beyond physical health, obesity is also associated with reduced quality of life, psychological distress, and social stigma.

The disease is increasingly recognized as a biologically regulated, chronic condition, requiring long-term management. Treatment approaches are multifaceted and include:

• Lifestyle modification and nutritional counseling
• Physical activity and behavioral therapy
• Pharmacotherapy
• Bariatric surgery in severe cases

Recent therapeutic advancements-particularly GLP-1 and dual incretin-based therapies-have significantly improved clinical outcomes, enabling sustained weight loss and transforming the treatment paradigm. Despite these advances, obesity remains a major global public health challenge, requiring scalable prevention strategies and personalized long-term care models.

Key Highlights

• The diagnosed obesity population in Germany is projected to grow significantly, increasing from 7.2 million in 2025 to 14.2 million by 2035, reflecting a high growth trajectory (7% CAGR).
• Obesity represents a high-prevalence, high-burden disease, with substantial long-term healthcare costs driven by associated comorbidities.
• Despite large patient numbers, treatment penetration remains low, with many patients managed primarily through lifestyle interventions.

Market Overview

• The obesity market is undergoing rapid expansion, driven by high-efficacy therapies and increasing treatment uptake.
• The obesity market in France is projected to grow from $410M in 2025 to $1.57Bn by 2035, reflecting a strong CAGR of 14-15%.
• The diagnosed population in Germany is expected to grow at ~7% CAGR, significantly expanding the addressable market.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Hanmi Pharmaceutical Company Limited
• Tonghua Dongbao Pharmaceutical Co.,Ltd
• Aphaia Pharma US LLC
• NeuroBiogen Co., Ltd
• Eli Lilly and Company
• MindRank AI Ltd
• Pfizer
• Kailera
• Glyscend, Inc.
• NodThera Limited
• Palatin Technologies, Inc
• BrightGene Bio-Medical Technology Co., Ltd.
• Aardvark Therapeutics, Inc.
• Alnylam Pharmaceuticals
• Guangdong Raynovent Biotech Co., Ltd
• Innovent Biologics (Suzhou) Co. Ltd.
• Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
• Fujian Shengdi Pharmaceutical Co., Ltd.
• Arrowhead Pharmaceuticals
• Hudson Biotech
• Zomagen Biosciences Ltd.
• Corxel Pharmaceuticals
• Regeneron Pharmaceuticals
• Regor Pharmaceuticals Inc.
• Boehringer Ingelheim
• Novo Nordisk A/S
• Skye Bioscience, Inc.
• Shionogi
• Amgen
• Rhythm Pharmaceuticals, Inc.
• Vanda Pharmaceuticals
• Kallyope Inc.
• Metsera, a wholly owned subsidiary of Pfizer
• S1 Biopharma, Inc.
• Biophytis
• AstraZeneca
• Shandong Suncadia Medicine Co., Ltd.
• Biohaven Therapeutics Ltd.
• Beijing QL Biopharmaceutical Co.,Ltd
• Rose Pharma Inc
• Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Vincentage Pharma Co., Ltd
• CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
• Gan and Lee Pharmaceuticals, USA
• Verdiva Bio Dev Limited
• Gan & Lee Pharmaceuticals.
• Carmot Therapeutics, Inc.
• Exerkine Corporation
• Terns, Inc.
• Chendu DIAO Pharmaceutical Group CO., LTD.
• Hangzhou Sciwind Biosciences Co., Ltd.
• The United Bio-Technology (Hengqin) Co., Ltd.
• Scholar Rock, Inc.
• Biomed Industries, Inc.
• Ikaria Bioscience Pty Ltd
• Hoffmann-La Roche
• HK inno.N Corporation
• Actimed Therapeutics Ltd
• Inversago Pharma Inc.
• Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.
• Immunwork, Inc.
• Veru Inc.
• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
• Neuraly, Inc.
• ARKAY Therapeutics

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)